- Home
- AMS vs CARA Comparison
AMS vs CARA Comparison
Compare AMS & CARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMS
- CARA
- Stock Information
- Founded
- AMS 1980
- CARA 2004
- Country
- AMS United States
- CARA United States
- Employees
- AMS 13
- CARA N/A
- Industry
- AMS Medical Specialities
- CARA Biotechnology: Pharmaceutical Preparations
- Sector
- AMS Health Care
- CARA Health Care
- Exchange
- AMS Nasdaq
- CARA Nasdaq
- Market Cap
- AMS 19.3M
- CARA 23.1M
- IPO Year
- AMS N/A
- CARA 2014
- Fundamental
- Price
- AMS $3.01
- CARA $4.97
- Analyst Decision
- AMS
- CARA Hold
- Analyst Count
- AMS 0
- CARA 3
- Target Price
- AMS N/A
- CARA $12.00
- AVG Volume (30 Days)
- AMS 4.3K
- CARA 25.1K
- Earning Date
- AMS 03-26-2025
- CARA 03-03-2025
- Dividend Yield
- AMS N/A
- CARA N/A
- EPS Growth
- AMS 779.12
- CARA N/A
- EPS
- AMS 0.61
- CARA N/A
- Revenue
- AMS $24,969,000.00
- CARA $8,686,000.00
- Revenue This Year
- AMS $27.74
- CARA N/A
- Revenue Next Year
- AMS $17.72
- CARA N/A
- P/E Ratio
- AMS $4.96
- CARA N/A
- Revenue Growth
- AMS 20.83
- CARA N/A
- 52 Week Low
- AMS $2.51
- CARA $2.71
- 52 Week High
- AMS $4.60
- CARA $13.80
- Technical
- Relative Strength Index (RSI)
- AMS 45.88
- CARA 49.66
- Support Level
- AMS $2.88
- CARA $4.94
- Resistance Level
- AMS $3.10
- CARA $5.73
- Average True Range (ATR)
- AMS 0.06
- CARA 0.30
- MACD
- AMS -0.01
- CARA -0.04
- Stochastic Oscillator
- AMS 40.33
- CARA 30.28
About AMS American Shared Hospital Services
American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates most of its revenue from the domestic market.
About CARA Cara Therapeutics Inc.
Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.